Chemotherapie-induzierte Polyneuropathie

Research output: Contribution to journalJournal articlesResearchpeer-review

Standard

Chemotherapie-induzierte Polyneuropathie. / Bobylev, I; Elter, T; Schneider, C; Wunderlich, G; Zimmer, P; Streckmann, F; Fink, G R; Lehmann, H C.

In: Fortschritte der Neurologie-Psychiatrie, Vol. 83, No. 8, 08.2015, p. 427-436.

Research output: Contribution to journalJournal articlesResearchpeer-review

Harvard

Bobylev, I, Elter, T, Schneider, C, Wunderlich, G, Zimmer, P, Streckmann, F, Fink, GR & Lehmann, HC 2015, 'Chemotherapie-induzierte Polyneuropathie', Fortschritte der Neurologie-Psychiatrie, vol. 83, no. 8, pp. 427-436. https://doi.org/10.1055/s-0035-1553475

APA

Bobylev, I., Elter, T., Schneider, C., Wunderlich, G., Zimmer, P., Streckmann, F., Fink, G. R., & Lehmann, H. C. (2015). Chemotherapie-induzierte Polyneuropathie. Fortschritte der Neurologie-Psychiatrie, 83(8), 427-436. https://doi.org/10.1055/s-0035-1553475

Vancouver

Bibtex

@article{78c5290dfd2a41c992970dc3e5ba0196,
title = "Chemotherapie-induzierte Polyneuropathie",
abstract = "Chemotherapy-induced peripheral neuropathy (CIPN) is a common and relevant side effect of antineoplastic agents such as cisplatin, paclitaxel, vincristine and bortezomib. Over the last years, significant progress has been achieved in elucidating the underlying pathomechanisms of CIPN using both in vivo and in vitro models. These studies suggest that mitochondrial toxicity, disturbed axonal transport, toxic effects on Schwann cells and activation of the immune system contribute to the pathogenesis of CIPN. This review provides an overview of the current pathogenetic concepts of CIPN. In addition, experimental approaches that aim at preventing or ameliorating neurotoxic effects of antineoplastic agents are discussed.",
author = "I Bobylev and T Elter and C Schneider and G Wunderlich and P Zimmer and F Streckmann and Fink, {G R} and Lehmann, {H C}",
note = "{\textcopyright} Georg Thieme Verlag KG Stuttgart · New York.",
year = "2015",
month = aug,
doi = "10.1055/s-0035-1553475",
language = "Deutsch",
volume = "83",
pages = "427--436",
journal = "Fortschritte der Neurologie-Psychiatrie",
issn = "0720-4299",
publisher = "Georg Thieme Verlag",
number = "8",

}

RIS

TY - JOUR

T1 - Chemotherapie-induzierte Polyneuropathie

AU - Bobylev, I

AU - Elter, T

AU - Schneider, C

AU - Wunderlich, G

AU - Zimmer, P

AU - Streckmann, F

AU - Fink, G R

AU - Lehmann, H C

N1 - © Georg Thieme Verlag KG Stuttgart · New York.

PY - 2015/8

Y1 - 2015/8

N2 - Chemotherapy-induced peripheral neuropathy (CIPN) is a common and relevant side effect of antineoplastic agents such as cisplatin, paclitaxel, vincristine and bortezomib. Over the last years, significant progress has been achieved in elucidating the underlying pathomechanisms of CIPN using both in vivo and in vitro models. These studies suggest that mitochondrial toxicity, disturbed axonal transport, toxic effects on Schwann cells and activation of the immune system contribute to the pathogenesis of CIPN. This review provides an overview of the current pathogenetic concepts of CIPN. In addition, experimental approaches that aim at preventing or ameliorating neurotoxic effects of antineoplastic agents are discussed.

AB - Chemotherapy-induced peripheral neuropathy (CIPN) is a common and relevant side effect of antineoplastic agents such as cisplatin, paclitaxel, vincristine and bortezomib. Over the last years, significant progress has been achieved in elucidating the underlying pathomechanisms of CIPN using both in vivo and in vitro models. These studies suggest that mitochondrial toxicity, disturbed axonal transport, toxic effects on Schwann cells and activation of the immune system contribute to the pathogenesis of CIPN. This review provides an overview of the current pathogenetic concepts of CIPN. In addition, experimental approaches that aim at preventing or ameliorating neurotoxic effects of antineoplastic agents are discussed.

U2 - 10.1055/s-0035-1553475

DO - 10.1055/s-0035-1553475

M3 - Zeitschriftenaufsätze

C2 - 26327474

VL - 83

SP - 427

EP - 436

JO - Fortschritte der Neurologie-Psychiatrie

JF - Fortschritte der Neurologie-Psychiatrie

SN - 0720-4299

IS - 8

ER -

ID: 1552080